← Back to patent-cliff list
Abimufloxacin
Tier C — Watch / tradeAbimufloxacin
Otsuka Pharmaceutical Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Topoisomerase IV, Bacterial DNA gyrase
Indications (approved)：Irritable bowel syndrome, Crohn's disease, Enteritis
Regional status
US
Discontinued
2020-02-25
EU
Discontinued
2020-02-25
China
Phase II
2023-08-02
Japan
No progress
2015-08-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Abimufloxacin?
Approved indications include: Irritable bowel syndrome, Crohn's disease, Enteritis.
When does the Abimufloxacin patent expire?
No public expiry year is available for Abimufloxacin yet; this page updates once verified.
How do I get a quote for Abimufloxacin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11